Search

Your search keyword '"Sin, Don D"' showing total 2,587 results
Start Over Author "Sin, Don D"
2,587 results on '"Sin, Don D"'

2. Multi-ancestry GWAS meta-analyses of lung cancer reveal susceptibility loci and elucidate smoking-independent genetic risk

Author

Gorman, Bryan R., Ji, Sun-Gou, Francis, Michael, Sendamarai, Anoop K., Shi, Yunling, Devineni, Poornima, Saxena, Uma, Partan, Elizabeth, DeVito, Andrea K., Byun, Jinyoung, Han, Younghun, Xiao, Xiangjun, Sin, Don D., Timens, Wim, Moser, Jennifer, Muralidhar, Sumitra, Ramoni, Rachel, Hung, Rayjean J., McKay, James D., Bossé, Yohan, Sun, Ryan, Amos, Christopher I., and Pyarajan, Saiju

Published
2024
Full Text
View/download PDF

3. An integrated cell atlas of the lung in health and disease

Author

Sikkema, Lisa, Ramírez-Suástegui, Ciro, Strobl, Daniel C, Gillett, Tessa E, Zappia, Luke, Madissoon, Elo, Markov, Nikolay S, Zaragosi, Laure-Emmanuelle, Ji, Yuge, Ansari, Meshal, Arguel, Marie-Jeanne, Apperloo, Leonie, Banchero, Martin, Bécavin, Christophe, Berg, Marijn, Chichelnitskiy, Evgeny, Chung, Mei-i, Collin, Antoine, Gay, Aurore CA, Gote-Schniering, Janine, Hooshiar Kashani, Baharak, Inecik, Kemal, Jain, Manu, Kapellos, Theodore S, Kole, Tessa M, Leroy, Sylvie, Mayr, Christoph H, Oliver, Amanda J, von Papen, Michael, Peter, Lance, Taylor, Chase J, Walzthoeni, Thomas, Xu, Chuan, Bui, Linh T, De Donno, Carlo, Dony, Leander, Faiz, Alen, Guo, Minzhe, Gutierrez, Austin J, Heumos, Lukas, Huang, Ni, Ibarra, Ignacio L, Jackson, Nathan D, Kadur Lakshminarasimha Murthy, Preetish, Lotfollahi, Mohammad, Tabib, Tracy, Talavera-López, Carlos, Travaglini, Kyle J, Wilbrey-Clark, Anna, Worlock, Kaylee B, Yoshida, Masahiro, van den Berge, Maarten, Bossé, Yohan, Desai, Tushar J, Eickelberg, Oliver, Kaminski, Naftali, Krasnow, Mark A, Lafyatis, Robert, Nikolic, Marko Z, Powell, Joseph E, Rajagopal, Jayaraj, Rojas, Mauricio, Rozenblatt-Rosen, Orit, Seibold, Max A, Sheppard, Dean, Shepherd, Douglas P, Sin, Don D, Timens, Wim, Tsankov, Alexander M, Whitsett, Jeffrey, Xu, Yan, Banovich, Nicholas E, Barbry, Pascal, Duong, Thu Elizabeth, Falk, Christine S, Meyer, Kerstin B, Kropski, Jonathan A, Pe’er, Dana, Schiller, Herbert B, Tata, Purushothama Rao, Schultze, Joachim L, Teichmann, Sara A, Misharin, Alexander V, Nawijn, Martijn C, Luecken, Malte D, and Theis, Fabian J

Subjects
Biomedical and Clinical Sciences, Health Sciences, Lung, Genetics, 2.1 Biological and endogenous factors, 1.1 Normal biological development and functioning, Generic health relevance, Respiratory, Good Health and Well Being, Humans, COVID-19, Pulmonary Fibrosis, Lung Neoplasms, Macrophages, Lung Biological Network Consortium, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Single-cell technologies have transformed our understanding of human tissues. Yet, studies typically capture only a limited number of donors and disagree on cell type definitions. Integrating many single-cell datasets can address these limitations of individual studies and capture the variability present in the population. Here we present the integrated Human Lung Cell Atlas (HLCA), combining 49 datasets of the human respiratory system into a single atlas spanning over 2.4 million cells from 486 individuals. The HLCA presents a consensus cell type re-annotation with matching marker genes, including annotations of rare and previously undescribed cell types. Leveraging the number and diversity of individuals in the HLCA, we identify gene modules that are associated with demographic covariates such as age, sex and body mass index, as well as gene modules changing expression along the proximal-to-distal axis of the bronchial tree. Mapping new data to the HLCA enables rapid data annotation and interpretation. Using the HLCA as a reference for the study of disease, we identify shared cell states across multiple lung diseases, including SPP1+ profibrotic monocyte-derived macrophages in COVID-19, pulmonary fibrosis and lung carcinoma. Overall, the HLCA serves as an example for the development and use of large-scale, cross-dataset organ atlases within the Human Cell Atlas.

Published
2023

5. Polygenic and transcriptional risk scores identify chronic obstructive pulmonary disease subtypes in the COPDGene and ECLIPSE cohort studies

Author

Moll, Matthew, Hecker, Julian, Platig, John, Zhang, Jingzhou, Ghosh, Auyon J., Pratte, Katherine A., Wang, Rui-Sheng, Hill, Davin, Konigsberg, Iain R., Chiles, Joe W., III, Hersh, Craig P., Castaldi, Peter J., Glass, Kimberly, Dy, Jennifer G., Sin, Don D., Tal-Singer, Ruth, Mouded, Majd, Rennard, Stephen I., Anderson, Gary P., Kinney, Gregory L., Bowler, Russell P., Curtis, Jeffrey L., McDonald, Merry-Lynn, Silverman, Edwin K., Hobbs, Brian D., and Cho, Michael H.

Published
2024
Full Text
View/download PDF

10. Abnormal Exertional Breathlessness on Cardiopulmonary Cycle Exercise Testing in Relation to Self-Reported and Physiologic Responses in Chronic Airflow Limitation

Author

Bourbeau, Jean, Tan, Wan C., FitzGerald, J. Mark, Sin, Don D., Marciniuk, Darcy D., O’Donnell, Denis E., Hernandez, Paul, Chapman, Kenneth R., Walker, Brandie, Aaron, Shawn, Maltais, François, Samet, Jonathon, Puhan, Milo, Hamid, Qutayba, Hogg, James C., Doiron, Dany, Mancino, Palmina, Li, Pei Zhi, Jensen, Dennis, Baglole, Carolyn, Fortier, Yvan, Sin, Don, Yang, Julia, Road, Jeremy, Comeau, Joe, Png, Adrian, Johnson, Kyle, Coxson, Harvey, Leipsic, Jonathon, Hague, Cameron, Kirby, Miranda, Sadatsafavi, Mohsen, To, Teresa, Gershon, Andrea, Li, Pei-Zhi, Song, Zhi, Benedetti, Andrea, Lo, Christine, Cheng, Sarah, Un, Elena, Fung, Cynthia, Wang, Wen Tiang, Zheng, Liyun, Faroon, Faize, Radivojevic, Olga, Chung, Sally, Zou, Carl, Baril, Jacinthe, Labonte, Laura, Chapman, Kenneth, McClean, Patricia, Audisho, Nadeen, Dumonceaux, Curtis, Machado, Lisette, Fulton, Scott, Osterling, Kristen, Wigerius, Denise, Vandemheen, Kathy, Pratt, Gay, Bergeron, Amanda, O’Donnell, Denis, McNeil, Matthew, Whelan, Kate, Brouillard, Cynthia, Marciniuk, Darcy, Clemens, Ron, Baran, Janet, Leuschen, Candice, Ekström, Magnus, and Lewthwaite, Hayley

Published
2024
Full Text
View/download PDF

11. Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease

Author

Hernández Cordero, Ana I, Yang, Chen Xi, Li, Xuan, Milne, Stephen, Chen, Virginia, Hollander, Zsuzsanna, Ng, Raymond, Criner, Gerard J, Woodruff, Prescott G, Lazarus, Stephen C, Connett, John E, Han, MeiLan K, Martinez, Fernando J, Reed, Robert M, Man, SF Paul, Leung, Janice M, and Sin, Don D

Subjects
Chronic Obstructive Pulmonary Disease, Lung, Genetics, Clinical Research, Prevention, Respiratory, Adult, Aged, Anti-Bacterial Agents, Azithromycin, Biomarkers, DNA Methylation, Disease Progression, Female, Follow-Up Studies, Hospitalization, Humans, Incidence, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive, Quality of Life, Retrospective Studies, Surveys and Questionnaires, Telomere, Time Factors, United States, COPD, Telomeres, AECOPD, Epigenetics, DNA methylation, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Respiratory System
Abstract

BackgroundChronic obstructive pulmonary disease (COPD) is an age-related condition that has been associated with early telomere attrition; the clinical implications of telomere shortening in COPD are not well known. In this study we aimed to determine the relationship of the epigenetic regulation of telomeric length in peripheral blood with the risk of exacerbations and hospitalization in patients with COPD.MethodsBlood DNA methylation profiles were obtained from 292 patients with COPD enrolled in the placebo arm of the Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated with Chronic Obstructive Pulmonary Disease (MACRO) Study and who were followed for 1-year. We calculated telomere length based on DNA methylation markers (DNAmTL) and related this biomarker to the risk of exacerbation and hospitalization and health status (St. George Respiratory Questionnaire [SGRQ]) score over time using a Cox proportional hazards model. We also used linear models to investigate the associations of DNAmTL with the rates of exacerbation and hospitalization (adjusted for chronological age, lung function, race, sex, smoking, body mass index and cell composition).ResultsParticipants with short DNAmTL demonstrated increased risk of exacerbation (P = 0.02) and hospitalization (P = 0.03) compared to those with longer DNAmTL. DNAmTL age acceleration was associated with higher rates of exacerbation (P = 1.35 × 10-04) and hospitalization (P = 5.21 × 10-03) and poor health status (lower SGRQ scores) independent of chronological age (P = 0.03).ConclusionTelomeric age based on blood DNA methylation is associated with COPD exacerbation and hospitalization and thus a promising biomarker for poor outcomes in COPD.

Published
2021

12. Author Correction: New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries

Author

Shrine, Nick, Guyatt, Anna L., Erzurumluoglu, A. Mesut, Jackson, Victoria E., Hobbs, Brian D., Melbourne, Carl A., Batini, Chiara, Fawcett, Katherine A., Song, Kijoung, Sakornsakolpat, Phuwanat, Li, Xingnan, Boxall, Ruth, Reeve, Nicola F., Obeidat, Ma’en, Zhao, Jing Hua, Wielscher, Matthias, Weiss, Stefan, Kentistou, Katherine A., Cook, James P., Sun, Benjamin B., Zhou, Jian, Hui, Jennie, Karrasch, Stefan, Imboden, Medea, Harris, Sarah E., Marten, Jonathan, Enroth, Stefan, Kerr, Shona M., Surakka, Ida, Vitart, Veronique, Lehtimäki, Terho, Allen, Richard J., Bakke, Per S., Beaty, Terri H., Bleecker, Eugene R., Bossé, Yohan, Brandsma, Corry-Anke, Chen, Zhengming, Crapo, James D., Danesh, John, DeMeo, Dawn L., Dudbridge, Frank, Ewert, Ralf, Gieger, Christian, Gulsvik, Amund, Hansell, Anna L., Hao, Ke, Hoffman, Joshua D., Hokanson, John E., Homuth, Georg, Joshi, Peter K., Joubert, Philippe, Langenberg, Claudia, Li, Xuan, Li, Liming, Lin, Kuang, Lind, Lars, Locantore, Nicholas, Luan, Jian’an, Mahajan, Anubha, Maranville, Joseph C., Murray, Alison, Nickle, David C., Packer, Richard, Parker, Margaret M., Paynton, Megan L., Porteous, David J., Prokopenko, Dmitry, Qiao, Dandi, Rawal, Rajesh, Runz, Heiko, Sayers, Ian, Sin, Don D., Smith, Blair H., Artigas, María Soler, Sparrow, David, Tal-Singer, Ruth, Timmers, Paul R. H. J., Van den Berge, Maarten, Whittaker, John C., Woodruff, Prescott G., Yerges-Armstrong, Laura M., Troyanskaya, Olga G., Raitakari, Olli T., Kähönen, Mika, Polašek, Ozren, Gyllensten, Ulf, Rudan, Igor, Deary, Ian J., Probst-Hensch, Nicole M., Schulz, Holger, James, Alan L., Wilson, James F., Stubbe, Beate, Zeggini, Eleftheria, Jarvelin, Marjo-Riitta, Wareham, Nick, Silverman, Edwin K., Hayward, Caroline, Morris, Andrew P., Butterworth, Adam S., Scott, Robert A., Walters, Robin G., Meyers, Deborah A., Cho, Michael H., Strachan, David P., Hall, Ian P., Tobin, Martin D., and Wain, Louise V.

Published
2024
Full Text
View/download PDF

13. TLR7 promotes smoke-induced experimental lung damage through the activity of mast cell tryptase

Author

Liu, Gang, Haw, Tatt Jhong, Starkey, Malcolm R., Philp, Ashleigh M., Pavlidis, Stelios, Nalkurthi, Christina, Nair, Prema M., Gomez, Henry M., Hanish, Irwan, Hsu, Alan CY., Hortle, Elinor, Pickles, Sophie, Rojas-Quintero, Joselyn, Estepar, Raul San Jose, Marshall, Jacqueline E., Kim, Richard Y., Collison, Adam M., Mattes, Joerg, Idrees, Sobia, Faiz, Alen, Hansbro, Nicole G., Fukui, Ryutaro, Murakami, Yusuke, Cheng, Hong Sheng, Tan, Nguan Soon, Chotirmall, Sanjay H., Horvat, Jay C., Foster, Paul S., Oliver, Brian GG., Polverino, Francesca, Ieni, Antonio, Monaco, Francesco, Caramori, Gaetano, Sohal, Sukhwinder S., Bracke, Ken R., Wark, Peter A., Adcock, Ian M., Miyake, Kensuke, Sin, Don D., and Hansbro, Philip M.

Published
2023
Full Text
View/download PDF

15. Microbial dysbiosis and the host airway epithelial response: insights into HIV-associated COPD using multi’omics profiling

Author

Jude, Marcia Smiti, Yang, Chen Xi, Filho, Fernando Studart Leitao, Hernandez Cordero, Ana I., Yang, Julia, Shaipanich, Tawimas, Li, Xuan, Lin, David, MacIsaac, Julie, Kobor, Michael S., Sinha, Sunita, Nislow, Corey, Singh, Amrit, Lam, Wan, Lam, Stephen, Guillemi, Silvia, Harris, Marianne, Montaner, Julio, Ng, Raymond T., Carlsten, Christopher, Paul Man, S. F., Sin, Don D., and Leung, Janice M.

Published
2023
Full Text
View/download PDF

16. Personal Interventions for Reducing Exposure and Risk for Outdoor Air Pollution: An Official American Thoracic Society Workshop Report

Author

Laumbach, Robert J, Cromar, Kevin R, Adamkiewicz, Gary, Carlsten, Christopher, Charpin, Denis, Chan, Wanyu R, de Nazelle, Audrey, Forastiere, Francesco, Goldstein, Jeffrey, Gumy, Sophie, Hallman, William K, Jerrett, Michael, Kipen, Howard M, Pirozzi, Cheryl S, Polivka, Barbara J, Radbel, Jared, Shaffer, Ronald E, Sin, Don D, and Viegi, Giovanni

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Climate-Related Exposures and Conditions, Social Determinants of Health, Prevention, Behavioral and Social Science, Respiratory, Good Health and Well Being, Sustainable Cities and Communities, Air Pollution, Humans, Reproducibility of Results, Transportation, United States, air pollution, exposure, personal intervention, air filtration, respirators, Cardiovascular medicine and haematology, Clinical sciences
Abstract

Poor air quality affects the health and wellbeing of large populations around the globe. Although source controls are the most effective approaches for improving air quality and reducing health risks, individuals can also take actions to reduce their personal exposure by staying indoors, reducing physical activity, altering modes of transportation, filtering indoor air, and using respirators and other types of face masks. A synthesis of available evidence on the efficacy, effectiveness, and potential adverse effects or unintended consequences of personal interventions for air pollution is needed by clinicians to assist patients and the public in making informed decisions about use of these interventions. To address this need, the American Thoracic Society convened a workshop in May of 2018 to bring together a multidisciplinary group of international experts to review the current state of knowledge about personal interventions for air pollution and important considerations when helping patients and the general public to make decisions about how best to protect themselves. From these discussions, recommendations were made regarding when, where, how, and for whom to consider personal interventions. In addition to the efficacy and safety of the various interventions, the committee considered evidence regarding the identification of patients at greatest risk, the reliability of air quality indices, the communication challenges, and the ethical and equity considerations that arise when discussing personal interventions to reduce exposure and risk from outdoor air pollution.

Published
2021

17. Trends in hospital admissions for chronic obstructive pulmonary disease over 16 years in Canada

Author

Amegadzie, Joseph E., Lee, Tae Yoon, Sadatsafavi, Mohsen, Lynd, Larry D., Sin, Don D., and Johnson, Kate M.

Subjects
Statistics, Care and treatment, Patient outcomes, Hospitalization -- Statistics, Chronic obstructive lung disease -- Statistics -- Care and treatment -- Patient outcomes, Hospital care -- Statistics, Lung diseases, Obstructive -- Statistics -- Care and treatment -- Patient outcomes
Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease that imposes a substantial burden on patients and Canadian health care systems. Despite plateauing rates of smoking, the burden [...], Background: Chronic obstructive pulmonary disease (COPD) is an ambulatory care-sensitive condition, and the rate of hospital admissions for COPD is an indicator of the quality of outpatient care. We sought to determine long-term trends in hospital admissions for COPD in Canada. Methods: Using a comprehensive national database of hospital admissions in Canada, we identified those with a main discharge diagnosis of COPD for patients aged 40 years and older between 2002 and 2017. We calculated sex-specific, age-standardized trends in annual rates of hospital admissions for COPD separately for younger (40-64 yr) and older adults ([greater than or equal to] 65 yr). We used spline regression to examine changes in the admissions trends for each sex and age group. Results: Over 16 years, 1 134 359 hospital admissions were for COPD. Between 2002 and 2017, the total number of admissions increased by 68.8%, from 52 937 to 89 384. The overall crude admission rate increased by 30.0%, from 368 to 479 per 100 000 population, and the sex- and age-standardized admission rate increased by 9.6%, from 437 to 479 per 100 000 population. Age-standardized rates increased by 12.2% among younger females, by 24.4% among younger males and by 29.8% among older females, but decreased by 9.0% among older males. Over the same period, the all-cause sex- and age-standardized admission rate declined by 23.0%. Interpretation: Hospital admissions for COPD have increased since 2010, even after adjusting for population growth and aging, and despite declining rates of all-cause hospital admissions. The secular increase in COPD admissions indicates that the burden of COPD on Canadian health care systems is increasing.

Published
2023
Full Text
View/download PDF

18. Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing

Author

FitzGerald, J. Mark, Sin, Don D., Marciniuk, Darcy D., O’Donnell, Denis E., Hernandez, Paul, Chapman, Kenneth R., Walker, Brandie, Aaron, Shawn, Maltais, François, Samet, Jonathon, Puhan, Milo, Hamid, Qutayba, Hogg, James C., Doiron, Dany, Mancino, Palmina, Li, Pei Zhi, Jensen, Dennis, Baglole, Carolyn, Fortier, Yvan, Sin, Don, Yang, Julia, Road, Jeremy, Comeau, Joe, Png, Adrian, Johnson, Kyle, Coxson, Harvey, Leipsic, Jonathon, Hague, Cameron, Kirby, Miranda, Sadatsafavi, Mohsen, To, Teresa, Gershon, Andrea, Song, Zhi, Benedetti, Andrea, Lo, Christine, Cheng, Sarah, Un, Elena, Fung, Cynthia, Wang, Wen Tiang, Zheng, Liyun, Faroon, Faize, Radivojevic, Olga, Chung, Sally, Zou, Carl, Baril, Jacinthe, Labonte, Laura, Chapman, Kenneth, McClean, Patricia, Audisho, Nadeen, Dumonceaux, Curtis, Machado, Lisette, Fulton, Scott, Osterling, Kristen, Wigerius, Denise, Vandemheen, Kathy, Pratt, Gay, Bergeron, Amanda, O’Donnell, Denis, McNeil, Matthew, Whelan, Kate, Brouillard, Cynthia, Marciniuk, Darcy, Clemens, Ron, Baran, Janet, Leuschen, Candice, Ekström, Magnus, Lewthwaite, Hayley, Bourbeau, Jean, and Tan, Wan C.

Published
2024
Full Text
View/download PDF

21. Impaired Spirometry and COPD Increase the Risk of Cardiovascular Disease: A Canadian Cohort Study

Author

FitzGerald, J. Mark, Sin, Don D., Marciniuk, Darcy D., O’Donnell, Denis E., Hernandez, Paul, Chapman, Kenneth R., Walker, Brandie, Aaron, Shawn, Maltais, François, Doiron, Dany, Mancino, Palmina, Li, Pei Zhi, Jensen, Dennis, Baglole, Carolyn, Fortier, Yvan, Sin, Don, Yang, Julia, Road, Jeremy, Comeau, Joe, Png, Adrian, Johnson, Kyle, Coxson, Harvey, Leipsic, Jonathon, Hague, Cameron, Kirby, Miranda, Song, Zhi, Benedetti, Andrea, Lo, Christine, Cheng, Sarah, Un, Elena, Fung, Cynthia, Wang, Wen Tiang, Zheng, Liyun, Faroon, Faize, Radivojevic, Olga, Chung, Sally, Zou, Carl, Bourbeau, Jean, Baril, Jacinthe, Labonte, Laura, Chapman, Kenneth, McClean, Patricia, Audisho, Nadeen, Dumonceaux, Curtis, Machado, Lisette, Fulton, Scott, Osterling, Kristen, Wigerius, Denise, Vandemheen, Kathy, Pratt, Gay, Bergeron, Amanda, O’Donnell, Denis, McNeil, Matthew, Whelan, Kate, Brouillard, Cynthia, Marciniuk, Darcy, Clemens, Ron, Baran, Janet, Leuschen, Candace, Krishnan, Suurya, Tan, Wan C., Farias, Raquel, and Aaron, Shawn D.

Published
2023
Full Text
View/download PDF

22. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary

Author

Agustí, Alvar, Celli, Bartolome R., Criner, Gerard J., Halpin, David, Anzueto, Antonio, Barnes, Peter, Bourbeau, Jean, Han, MeiLan K., Martinez, Fernando J., Montes de Oca, Maria, Mortimer, Kevin, Papi, Alberto, Pavord, Ian, Roche, Nicolas, Salvi, Sundeep, Sin, Don D., Singh, Dave, Stockley, Robert, López Varela, M. Victorina, Wedzicha, Jadwiga A., and Vogelmeier, Claus F.

Published
2023
Full Text
View/download PDF

23. Generalizability of Risk Stratification Algorithms for Exacerbations in COPD

Author

Bansback, Nick, Bottorff, Joan L., Bryan, Stirling, Burns, Paloma, Carlsten, Chris, Conklin, Annalijn I., De Vera, Mary, Gershon, Andrea, Gupta, Samir, Gustafson, Paul, Harvard, Stephanie, Hoens, Alison M., Mokhtaran, Mehrshad, Johnson, Jim, Joshi, Phalgun, Leung, Janice, Lynd, Larry D., Metcalfe, Rebecca K., Michaux, Kristina D., Sadatsafavi, Mohsen, Simmers, Brian, Sin, Don D., Smith, Daniel, Struik, Laura, Vinay, Dhingra, Ho, Joseph Khoa, Safari, Abdollah, Adibi, Amin, and Johnson, Kate

Published
2023
Full Text
View/download PDF

24. Impaired Sleep Quality in COPD Is Associated With Exacerbations The CanCOLD Cohort Study

Author

Shorofsky, Matthew, Bourbeau, Jean, Kimoff, John, Jen, Rachel, Malhotra, Atul, Ayas, Najib, Tan, Wan C, Aaron, Shawn D, Sin, Don D, Road, Jeremy, Chapman, Kenneth R, O’Donnell, Denis E, Maltais, François, Hernandez, Paul, Walker, Brandie L, Marciniuk, Darcy, Kaminska, Marta, FitzGerald, J Mark, Sin, DD, Marciniuk, DD, O'Donnell, DE, Cowie, Robert, Aaron, Shawn, Maltais, F, Samet, Jonathon, Puhan, Milo, Hamid, Qutayba, Hogg, James C, Baglole, Carole, Jabet, Carole, Mancino, Palmina, Fortier, Yvan, Sin, Don, Tam, Sheena, Comeau, Joe, Png, Adrian, Coxson, Harvey, Kirby, Miranda, Leipsic, Jonathon, Hague, Cameron, Sadatsafavi, Mohsen, Gershon, Andrea, Li, Pei-Zhi, Duquette, Jean-Francois, Benedetti, Andrea, Jensen, Denis, O'Donnell, Denis, Lo, Christine, Cheng, Sarah, Fung, Cindy, Ferguson, Nancy, Haynes, Nancy, Chuang, Li, Licong, Bayat, Selva, Wong, Amanda, Alavi, Zoe, Peng, Catherine, Zhao, Bin, Scott-Hsiung, Nathalie, Nadirshaw, Tasha, Latreille, David, Baril, Jacinthe, Labonte, Laura, Chapman, Kenneth, McClean, Patricia, Audisho, Nadeen, Walker, Brandie, Cowie, Ann, Dumonceaux, Curtis, Machado, Lisette, Fulton, Scott, Osterling, Kristen, Vandemheen, Kathy, Pratt, Gay, Bergeron, Amanda, McNeil, Matthew, Whelan, Kate, Maltais, Francois, Brouillard, Cynthia, and Clemens, Ron

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Prevention, Chronic Obstructive Pulmonary Disease, Lung, Sleep Research, Clinical Research, 6.1 Pharmaceuticals, Respiratory, Aged, Cohort Studies, Disease Progression, Dyspnea, Female, Health Services, Humans, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Pulmonary Disease, Chronic Obstructive, Sleep, Sleep Wake Disorders, Sputum, Time Factors, acute exacerbation of chronic bronchitis, COPD, sleep medicine, Canadian Respiratory Research Network, CanCOLD Collaborative Research group, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundCOPD increases susceptibility to sleep disturbances, which may in turn predispose to increased respiratory symptoms. The objective of this study was to evaluate, in a population-based sample, the relationship between subjective sleep quality and risk of COPD exacerbations.MethodsData were obtained from the Canadian Cohort Obstructive Lung Disease (CanCOLD) study. Participants with COPD who had completed 18 months of follow-up were included. Sleep quality was measured with the Pittsburgh Sleep Quality Index (PSQI) and a three-factor analysis. Symptom-based (dyspnea or sputum change ≥ 48 h) and event-based (symptoms plus medication or unscheduled health services use) exacerbations were assessed. Association of PSQI with exacerbation rate was assessed by using negative binomial regression. Exacerbation-free survival was also assessed.ResultsA total of 480 participants with COPD were studied, including 185 with one or more exacerbations during follow-up and 203 with poor baseline sleep quality (PSQI score > 5). Participants with subsequent symptom-based exacerbations had higher median baseline PSQI scores than those without (6.0 [interquartile range, 3.0-8.0] vs 5.0 [interquartile range, 2.0-7.0]; P = .01), and they were more likely to have baseline PSQI scores > 5 (50.3% vs 37.3%; P = .01). Higher PSQI scores were associated with increased symptom-based exacerbation risk (adjusted rate ratio, 1.09; 95% CI, 1.01-1.18; P = .02) and event-based exacerbation risk (adjusted rate ratio, 1.10; 95% CI, 1.00-1.21; P = .048). The association occurred mainly in those with undiagnosed COPD. Strongest associations were with Factor 3 (sleep disturbances and daytime dysfunction). Time to symptom-based exacerbation was shorter in participants with poor sleep quality (adjusted hazard ratio, 1.49; 95% CI, 1.09-2.03).ConclusionsHigher baseline PSQI scores were associated with increased risk of COPD exacerbation over 18 months' prospective follow-up.

Published
2019

27. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission

Author

Stolz, Daiana, Mkorombindo, Takudzwa, Schumann, Desiree M, Agusti, Alvar, Ash, Samuel Y, Bafadhel, Mona, Bai, Chunxue, Chalmers, James D, Criner, Gerard J, Dharmage, Shyamali C, Franssen, Frits M E, Frey, Urs, Han, MeiLan, Hansel, Nadia N, Hawkins, Nathaniel M, Kalhan, Ravi, Konigshoff, Melanie, Ko, Fanny W, Parekh, Trisha M, Powell, Pippa, Rutten-van Mölken, Maureen, Simpson, Jodie, Sin, Don D, Song, Yuanlin, Suki, Bela, Troosters, Thierry, Washko, George R, Welte, Tobias, and Dransfield, Mark T

Published
2022
Full Text
View/download PDF

29. The relationship between the epigenetic aging biomarker “grimage” and lung function in both the airway and blood of people living with HIV: An observational cohort study

Author

Baker, J.V., Duprez, D., Carr, A., Hoy, J., Dolan, M., Telenti, A., Grady, C., Matthews, G., Rockstroh, J., Belloso, W.H., Kagan, J.M., Wright, E., Brew, B., Price, R.W., Robertson, K., Cysique, L., Kunisaki, K.M., Connett, J.E., Niewoehner, D.E., Endpoint Review Committee, Lifson, A., Davey, R.T., Jr., Gatell, J.M., Pedersen, C., Prineas, R., Worley, J., Hernández Cordero, Ana I, Yang, Chen Xi, Yang, Julia, Li, Xuan, Horvath, Steve, Shaipanich, Tawimas, MacIsaac, Julia, Lin, David, McEwen, Lisa, Kobor, Michael S., Guillemi, Silvia, Harris, Marianne, Lam, Wan, Lam, Stephen, Obeidat, Ma'en, Novak, Richard M., Hudson, Fleur, Klinker, Hartwig, Dharan, Nila, Montaner, Julio, Man, S.F. Paul, Kunisaki, Ken, Sin, Don D., and Leung, Janice M.

Published
2022
Full Text
View/download PDF

31. Granzyme B May Act as an Effector Molecule to Control the Inflammatory Process in COPD.

Author

Kim, Won-Dong and Sin, Don D.

Subjects
*REGULATORY B cells, *REGULATORY T cells, *CHRONIC obstructive pulmonary disease, *ENZYME-linked immunosorbent assay, *IMMUNOSTAINING
Abstract

Chronic obstructive pulmonary disease (COPD) is caused by smoking, but only a small proportion of smokers have disease severe enough to develop COPD. COPD is not always progressive. The question then arises as to what explains the different trajectories of COPD. The role of autoimmunity and regulatory T (Treg) cells in the pathogenesis of COPD is increasingly being recognized. Nine published studies on Treg cells in the lung tissue or bronchoalveolar lavage fluid have shown that smokers with COPD have fewer Treg cells than smokers without COPD or nonsmokers. Three studies showed a positive correlation between Treg cell count and FEV1%, suggesting an important role for Treg cells in COPD progression. Treg cells can regulate immunological responses via the granzyme B (GzmB) pathway. Immunohistochemical staining for GzmB in surgically resected lungs with centrilobular emphysema showed that the relationship between the amount of GzmB+ cells and FEV1% was comparable to that between Treg cell count and FEV1% in the COPD lung, suggesting that GzmB could be a functional marker for Treg cells. The volume fraction of GzmB+ cells in the small airways, the number of alveolar GzmB+ cells, and GzmB expression measured by enzyme-linked immunosorbent assay in the lung tissue of smokers were significantly correlated with FEV1%. These results suggest that the GzmB content in lung tissue may determine the progression of COPD by acting as an effector molecule to control inflammatory process. Interventions to augment GzmB-producing immunosuppressive cells in the early stages of COPD could help prevent or delay COPD progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Genetic Associations and Architecture of Asthma-COPD Overlap

Author

John, Catherine, Guyatt, Anna L., Shrine, Nick, Packer, Richard, Olafsdottir, Thorunn A., Liu, Jiangyuan, Hayden, Lystra P., Chu, Su H., Koskela, Jukka T., Luan, Jian’an, Li, Xingnan, Terzikhan, Natalie, Xu, Hanfei, Bartz, Traci M., Petersen, Hans, Leng, Shuguang, Belinsky, Steven A., Cepelis, Aivaras, Hernández Cordero, Ana I., Obeidat, Ma’en, Thorleifsson, Gudmar, Meyers, Deborah A., Bleecker, Eugene R., Sakoda, Lori C., Iribarren, Carlos, Tesfaigzi, Yohannes, Gharib, Sina A., Dupuis, Josée, Brusselle, Guy, Lahousse, Lies, Ortega, Victor E., Jonsdottir, Ingileif, Sin, Don D., Bossé, Yohan, van den Berge, Maarten, Nickle, David, Quint, Jennifer K., Sayers, Ian, Hall, Ian P., Langenberg, Claudia, Ripatti, Samuli, Laitinen, Tarja, Wu, Ann C., Lasky-Su, Jessica, Bakke, Per, Gulsvik, Amund, Hersh, Craig P., Hayward, Caroline, Langhammer, Arnulf, Brumpton, Ben, Stefansson, Kari, Cho, Michael H., Wain, Louise V., and Tobin, Martin D.

Published
2022
Full Text
View/download PDF

33. Karma of Cardiovascular Disease Risk Factors for Prevention and Management of Major Cardiovascular Events in the Context of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Author

Crisan, Liliana, Wong, Nathan, Sin, Don D, and Lee, Hwa Mu

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cardiovascular, Prevention, Tobacco, Lung, Clinical Research, Chronic Obstructive Pulmonary Disease, Heart Disease, Tobacco Smoke and Health, Infectious Diseases, Respiratory, Good Health and Well Being, chronic obstructive pulmonary disease, acute exacerbation of COPD, cardiovascular diseases, major adverse cardiovascular events, risk factors, Cardiovascular medicine and haematology
Abstract

There is compelling epidemiological evidence that airway exposure to cigarette smoke, air pollution particles, as well as bacterial and viral pathogens is strongly related to acute ischemic events. Over the years, there have been important animal and human studies that have provided experimental evidence to support a causal link. Studies show that patients with cardiovascular diseases (CVDs) or risk factors for CVD are more likely to have major adverse cardiovascular events (MACEs) after an acute exacerbation of chronic obstructive pulmonary disease (COPD), and patients with more severe COPD have higher cardiovascular mortality and morbidity than those with less severe COPD. The risk of MACEs in acute exacerbation of COPD is determined by the complex interactions between genetics, behavioral, metabolic, infectious, and environmental risk factors. To date, there are no guidelines regarding the prevention, screening, and management of the modifiable risk factors for MACEs in the context of COPD or COPD exacerbations, and there is insufficient CVD risk control in those with COPD. A deeper insight of the modifiable risk factors shared by CVD, COPD, and acute exacerbations of COPD may improve the strategies for reduction of MACEs in patients with COPD through vaccination, tight control of traditional CV risk factors and modifying lifestyle. This review summarizes the most recent studies regarding the pathophysiology and epidemiology of modifiable risk factors shared by CVD, COPD, and COPD exacerbations that could influence overall morbidity and mortality due to MACEs in patients with acute exacerbations of COPD.

Published
2019

34. Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD

Author

Leitao Filho, Fernando Sergio, Ra, Seung Won, Mattman, Andre, Schellenberg, Robert S, Criner, Gerard J, Woodruff, Prescott G, Lazarus, Stephen C, Albert, Richard, Connett, John E, Han, Meilan K, Martinez, Fernando J, Leung, Janice M, Paul Man, SF, Aaron, Shawn D, Reed, Robert M, Sin, Don D, and for the Canadian Respiratory Research Network (CRRN)

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Prevention, Clinical Research, Lung, Chronic Obstructive Pulmonary Disease, Respiratory, Aged, Biomarkers, Double-Blind Method, Female, Hospitalization, Humans, IgG Deficiency, Immunoglobulin G, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive, Retrospective Studies, Risk Factors, IgG, IgG subclass deficiency, COPD, Exacerbation, Canadian Respiratory Research Network, Cardiorespiratory Medicine and Haematology, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundThe literature is scarce regarding the prevalence and clinical impact of IgG subclass deficiency in COPD. We investigated the prevalence of IgG subclass deficiencies and their association with exacerbations and hospitalizations using subjects from two COPD cohorts.MethodsWe measured IgG subclass levels using immunonephelometry in serum samples from participants enrolled in two previous COPD trials: Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO; n = 976) and Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE; n = 653). All samples were collected from clinically stable participants upon entry into both studies. IgG subclass deficiency was diagnosed when IgG subclass levels were below their respective lower limit of normal: IgG1

Published
2018

35. Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function.

Author

Wyss, Annah B, Sofer, Tamar, Lee, Mi Kyeong, Terzikhan, Natalie, Nguyen, Jennifer N, Lahousse, Lies, Latourelle, Jeanne C, Smith, Albert Vernon, Bartz, Traci M, Feitosa, Mary F, Gao, Wei, Ahluwalia, Tarunveer S, Tang, Wenbo, Oldmeadow, Christopher, Duan, Qing, de Jong, Kim, Wojczynski, Mary K, Wang, Xin-Qun, Noordam, Raymond, Hartwig, Fernando Pires, Jackson, Victoria E, Wang, Tianyuan, Obeidat, Ma'en, Hobbs, Brian D, Huan, Tianxiao, Gui, Hongsheng, Parker, Margaret M, Hu, Donglei, Mogil, Lauren S, Kichaev, Gleb, Jin, Jianping, Graff, Mariaelisa, Harris, Tamara B, Kalhan, Ravi, Heckbert, Susan R, Paternoster, Lavinia, Burkart, Kristin M, Liu, Yongmei, Holliday, Elizabeth G, Wilson, James G, Vonk, Judith M, Sanders, Jason L, Barr, R Graham, de Mutsert, Renée, Menezes, Ana Maria Baptista, Adams, Hieab HH, van den Berge, Maarten, Joehanes, Roby, Levin, Albert M, Liberto, Jennifer, Launer, Lenore J, Morrison, Alanna C, Sitlani, Colleen M, Celedón, Juan C, Kritchevsky, Stephen B, Scott, Rodney J, Christensen, Kaare, Rotter, Jerome I, Bonten, Tobias N, Wehrmeister, Fernando César, Bossé, Yohan, Xiao, Shujie, Oh, Sam, Franceschini, Nora, Brody, Jennifer A, Kaplan, Robert C, Lohman, Kurt, McEvoy, Mark, Province, Michael A, Rosendaal, Frits R, Taylor, Kent D, Nickle, David C, Williams, L Keoki, Burchard, Esteban G, Wheeler, Heather E, Sin, Don D, Gudnason, Vilmundur, North, Kari E, Fornage, Myriam, Psaty, Bruce M, Myers, Richard H, O'Connor, George, Hansen, Torben, Laurie, Cathy C, Cassano, Patricia A, Sung, Joohon, Kim, Woo Jin, Attia, John R, Lange, Leslie, Boezen, H Marike, Thyagarajan, Bharat, Rich, Stephen S, Mook-Kanamori, Dennis O, Horta, Bernardo Lessa, Uitterlinden, André G, Im, Hae Kyung, Cho, Michael H, Brusselle, Guy G, and Gharib, Sina A

Subjects
Lung, Humans, Lung Diseases, Pulmonary Disease, Chronic Obstructive, Genetic Predisposition to Disease, Vital Capacity, Forced Expiratory Volume, Regression Analysis, Sample Size, Smoking, Genomics, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Quantitative Trait Loci, African Continental Ancestry Group, Asian Americans, European Continental Ancestry Group, Hispanic Americans, Female, Male, Genome-Wide Association Study, Polymorphism, Single Nucleotide, Pulmonary Disease, Chronic Obstructive
Abstract

Nearly 100 loci have been identified for pulmonary function, almost exclusively in studies of European ancestry populations. We extend previous research by meta-analyzing genome-wide association studies of 1000 Genomes imputed variants in relation to pulmonary function in a multiethnic population of 90,715 individuals of European (N = 60,552), African (N = 8429), Asian (N = 9959), and Hispanic/Latino (N = 11,775) ethnicities. We identify over 50 additional loci at genome-wide significance in ancestry-specific or multiethnic meta-analyses. Using recent fine-mapping methods incorporating functional annotation, gene expression, and differences in linkage disequilibrium between ethnicities, we further shed light on potential causal variants and genes at known and newly identified loci. Several of the novel genes encode proteins with predicted or established drug targets, including KCNK2 and CDK12. Our study highlights the utility of multiethnic and integrative genomics approaches to extend existing knowledge of the genetics of lung function and clinical relevance of implicated loci.

Published
2018

42. DNA Methylation Demonstrates Bronchoalveolar Cell Senescence in People Living with HIV: An Observational Cohort Study

Author

Hernandez Cordero, Ana I., primary, Li, Xuan, additional, Yang, Julia, additional, Yang, Chen Xi, additional, Shaipanich, Tawimas, additional, MacIsaac, Julie L., additional, Dever, Kristy, additional, Kobor, Michael S., additional, Montaner, Julio, additional, Harris, Marianne, additional, Guillemi, Silvia, additional, Man, Shu Fan Paul, additional, Sin, Don D., additional, and Leung, Janice M., additional

Published
2024
Full Text
View/download PDF

43. Leveraging CT Imaging to Detect COPD and Concomitant Chronic Diseases

Author

Labaki, Wassim W., primary, Agusti, Alvar, additional, Bhatt, Surya P, additional, Bodduluri, Sandeep, additional, Criner, Gerard J., additional, Fabbri, Leonardo M, additional, Halpin, David M.G., additional, Lynch, David A., additional, Mannino, David M., additional, Miravitlles, Marc, additional, Papi, Alberto, additional, Sin, Don D, additional, Washko, George R, additional, Kazerooni, Ella A., additional, and Han, MeiLan K., additional

Published
2024
Full Text
View/download PDF

46. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

Author

Ra, Seung Won, Sze, Marc A, Lee, Eun Chong, Tam, Sheena, Oh, Yeni, Fishbane, Nick, Criner, Gerard J, Woodruff, Prescott G, Lazarus, Stephen C, Albert, Richard, Connett, John E, Han, Meilan K, Martinez, Fernando J, Aaron, Shawn D, Reed, Robert M, Man, SF Paul, Sin, Don D, and on behalf of the Canadian Respiratory Research Network

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Lung, Chronic Obstructive Pulmonary Disease, Respiratory, Aged, Anti-Bacterial Agents, Antibodies, Bacterial, Azithromycin, Biomarkers, C-Reactive Protein, Disease Progression, Disease-Free Survival, Female, Helicobacter Infections, Helicobacter pylori, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Pulmonary Disease, Chronic Obstructive, Receptors, Tumor Necrosis Factor, Type II, Risk Factors, Serologic Tests, Time Factors, Treatment Outcome, COPD, Exacerbation, Canadian Respiratory Research Network, Cardiorespiratory Medicine and Haematology, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

BackgroundHelicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients.MethodsPlasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured.ResultsOne hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p

Published
2017

47. American Thoracic Society/National Heart, Lung, and Blood Institute Asthma-Chronic Obstructive Pulmonary Disease Overlap Workshop Report.

Author

Woodruff, Prescott G, van den Berge, Maarten, Boucher, Richard C, Brightling, Christopher, Burchard, Esteban G, Christenson, Stephanie A, Han, MeiLan K, Holtzman, Michael J, Kraft, Monica, Lynch, David A, Martinez, Fernando D, Reddel, Helen K, Sin, Don D, Washko, George R, Wenzel, Sally E, Punturieri, Antonello, Freemer, Michelle M, and Wise, Robert A

Subjects
Lung, Asthma, Pulmonary Disease, Chronic Obstructive, Diagnostic Imaging, Societies, Medical, United States, National Heart, Lung, and Blood Institute (U.S.), asthma, chronic obstructive pulmonary disease, overlap, Clinical Research, Chronic Obstructive Pulmonary Disease, Respiratory, Medical and Health Sciences, Respiratory System
Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are highly prevalent chronic obstructive lung diseases with an associated high burden of disease. Asthma, which is often allergic in origin, frequently begins in infancy or childhood with variable airflow obstruction and intermittent wheezing, cough, and dyspnea. Patients with COPD, in contrast, are usually current or former smokers who present after the age of 40 years with symptoms (often persistent) including dyspnea and a productive cough. On the basis of age and smoking history, it is often easy to distinguish between asthma and COPD. However, some patients have features compatible with both diseases. Because clinical studies typically exclude these patients, their underlying disease mechanisms and appropriate treatment remain largely uncertain. To explore the status of and opportunities for research in this area, the NHLBI, in partnership with the American Thoracic Society, convened a workshop of investigators in San Francisco, California on May 14, 2016. At the workshop, current understanding of asthma-COPD overlap was discussed among clinicians, pathologists, radiologists, epidemiologists, and investigators with expertise in asthma and COPD. They considered knowledge gaps in our understanding of asthma-COPD overlap and identified strategies and research priorities that will advance its understanding. This report summarizes those discussions.

Published
2017

50. Phenotypic and functional translation of IL33 genetics in asthma

Author

Ketelaar, Maria E., Portelli, Michael A., Dijk, F. Nicole, Shrine, Nick, Faiz, Alen, Vermeulen, Cornelis J., Xu, Cheng J., Hankinson, Jenny, Bhaker, Sangita, Henry, Amanda P., Billington, Charlote K., Shaw, Dominick E., Johnson, Simon R., Benest, Andrew V., Pang, Vincent, Bates, David O., Pogson, Z.E.K., Fogarty, Andrew, McKeever, Tricia M., Singapuri, Amisha, Heaney, Liam G., Mansur, Adel H., Chaudhuri, Rekha, Thomson, Neil C., Holloway, John W., Lockett, Gabrielle A., Howarth, Peter H., Niven, Robert, Simpson, Angela, Tobin, Martin D., Hall, Ian P., Wain, Louise V., Blakey, John D., Brightling, Christopher E., Obeidat, Ma'en, Sin, Don D., Nickle, David C., Bossé, Yohan, Vonk, Judith M., van den Berge, Maarten, Koppelman, Gerard H., Sayers, Ian, and Nawijn, Martijn C.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results